AQUINOX PHARMACEUTICALS, INC Human Resources Contracts & Agreements
38 Contracts & Agreements
- Bonus & Incentive Agreements (6 contracts)
- Consulting Agreements (7)
- Employment Agreements (19)
- Retention Agreements (1)
- Separation Agreements (5)
- Amended and Restated Consulting Agreement with Stuart Cobb Consulting Ltd. dated April 19, 2024 (Filed With SEC on May 10, 2024)
- EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on May 10, 2024)
- EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on May 10, 2024)
- Fourth Amendment to the Consulting Agreement, dated January 1, 2023, by and between Neurogene Inc. and Stuart Cobb Consulting Ltd (Filed With SEC on December 19, 2023)
- Third Amendment to the Consulting Agreement, dated April 1, 2022, by and between Neurogene Inc. and Stuart Cobb Consulting Ltd (Filed With SEC on December 19, 2023)
- Second Amendment to the Consulting Agreement, dated January 1, 2020, by and between Neurogene Inc. and Stuart Cobb Consulting Ltd (Filed With SEC on December 19, 2023)
- First Amendment to the Consulting Agreement, dated July 13, 2020, by and between Neurogene Inc. and Stuart Cobb Consulting Ltd (Filed With SEC on December 19, 2023)
- Consulting Agreement, dated December 12, 2018, by and between Neurogene Inc. and Stuart Cobb Consulting Ltd (Filed With SEC on December 19, 2023)
- Employment Letter, dated January 7, 2019, by and between Neurogene Inc. and Rachel McMinn (Filed With SEC on December 19, 2023)
- Employment Letter, dated September 1, 2019, by and between Neurogene Inc. and Christine Mikail Cvijic (Filed With SEC on December 19, 2023)
- Consulting Agreement, dated December 17, 2023, by and between Neoleukin Therapeutics, Inc. and Donna Cochener (Filed With SEC on December 19, 2023)
- Form of Separation Agreement, by and between Neoleukin Therapeutics, Inc. and Sean Smith (Filed With SEC on December 19, 2023)
- Form of Separation Agreement, by and between Neoleukin Therapeutics, Inc. and Donna Cochener (Filed With SEC on December 19, 2023)
- Neurogene Inc. 2023 Equity Incentive Plan (Filed With SEC on December 19, 2023)
- Employment Agreement Amendment dated as of April 3, 2023 and effective March 31, 2023, by and between Neoleukin Therapeutics, Inc. and Sean Smith (Filed With SEC on May 8, 2023)
- Employment Agreement dated (Filed With SEC on May 8, 2023)
- Employment Agreement Amendment dated as of April 3, 2023 and effective March 31, 2023, by and between Neoleukin Therapeutics, Inc. and Donna Cochener (Filed With SEC on May 8, 2023)
- Separation Agreement dated March 6, 2023 and effective March 31, 2023, by and between Neoleukin Therapeutics, Inc. and Jonathan Drachman (Filed With SEC on May 8, 2023)
- Separation Agreement dated March 31, 2023, by and between Neoleukin Therapeutics, Inc. and Priti Patel (Filed With SEC on May 8, 2023)
- Employment Agreement, dated March 4, 2022, by and between Neoleukin Therapeutics, Inc. and Donna Cochener (Filed With SEC on March 20, 2023)
- Employment Agreement, dated April 14, 2021, by and between Neoleukin Therapeutics, Inc. and Priti Patel (Filed With SEC on March 1, 2022)
- Neoleukin Therapeutics, Inc. Amended and Restated 2014 Equity Incentive Plan (Filed With SEC on May 14, 2021)
- Executive Employment Agreement, dated September 29, 2020, by and between Neoleukin Therapeutics, Inc., and Holly Vance (Filed With SEC on March 25, 2021)
- Forms of Restricted Stock Unit Agreement and Restricted Stock Unit Grant Notice for Registrants 2014 Equity Incentive Plan (Filed With SEC on August 12, 2020)
- Employment Agreement, dated March 16, 2020, by and between Neoleukin Therapeutics, Inc. and Robert Ho (Filed With SEC on May 6, 2020)
- Amended and Restated Executive Employment Agreement, dated April 15, 2020, by and between Neoleukin Therapeutics, Inc., and Jonathan G. Drachman (Filed With SEC on April 17, 2020)
- Neoleukin Therapeutics, Inc. 2014 Equity Incentive Plan, as amended November 12, 2019 (Filed With SEC on November 14, 2019)
- Transition Retention Agreement, dated August 5, 2019, by and between Aquinox Pharmaceuticals, Inc., and Kamram Alam (Filed With SEC on August 6, 2019)
- Employment Agreement, dated August 5, 2019, by and between Aquinox Pharmaceuticals, Inc., and Jonathan G. Drachman (Filed With SEC on August 6, 2019)
- Separation Agreement and Release, dated August 5, 2019, by and between Aquinox Pharmaceuticals, Inc., and David J. Main (Filed With SEC on August 6, 2019)
- Executive Employment Agreement Amendment for Kamran Alam (Filed With SEC on August 1, 2019)
- Executive Employment Agreement Amendment for David Main (Filed With SEC on August 1, 2019)
- Executive Employment Agreement Amendment for David Main (Filed With SEC on November 7, 2018)
- Form of Executive Employment Agreement Amendment (AQXP Canada) (Filed With SEC on November 7, 2018)
- EXECUTIVE EMPLOYMENT AGREEMENT for [Name] (Filed With SEC on March 14, 2016)
- Form of Executive Employment Agreement (Filed With SEC on November 4, 2014)
- AQUINOX PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN OPTION AGREEMENT (INCENTIVE STOCK OPTION OR NONSTATUTORY STOCKOPTION) (U.S. OPTIONHOLDERS) (Filed With SEC on January 28, 2014)
- AQUINOX PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:JANUARY 12, 2014 APPROVED BY THE STOCKHOLDERS:JANUARY 27, 2014 EFFECTIVE DATE:[ ], 2014... (Filed With SEC on January 28, 2014)
